• Actuate Therapeutics published results from a randomized, open-label Phase II trial in untreated metastatic pancreatic ductal adenocarcinoma.
• Study tested FOLFIRINOX combined with GSK-3β inhibitor elraglusib, TGF-β inhibitor losartan, or both in a four-arm, non-comparator design.
• Primary endpoint was progression-free survival; secondary endpoints included overall survival, objective response rate, time on maintenance therapy, baseline characteristics.
• Outcomes did not beat historical standards, though Arms 3 and 4 showed deep, durable responses in a subset of patients.
• Treatment was generally tolerated; one treatment-related death from sepsis occurred in Arm 3.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actuate Therapeutics Inc. published the original content used to generate this news brief on May 30, 2026, and is solely responsible for the information contained therein.